EMVision Medical Devices Advances Brain Scanner Trials
EMvision Medical Devices Ltd. (AU:EMV) has released an update.
EMVision Medical Devices Ltd has completed recruitment for its ‘EMView’ multi-centre pre-validation trial, enrolling over 300 participants, with Stage 3 results expected in November. The company unveiled its transformative, ultra-lightweight First Responder brain scanner, designed for rapid stroke diagnosis, and is progressing towards a road and air study. With a strong cash reserve and support from non-dilutive funding, EMVision is well-positioned to advance its innovative neurodiagnostic technology.
For further insights into AU:EMV stock, check out TipRanks’ Stock Analysis page.
TipRanks is the most comprehensive data set of sell side analysts and hedge fund managers. TipRanks' multi-award winning platform ranks financial experts based on measured performance and the accuracy of their predictions so investors know who to trust when making investment decisions.